You are here: Industry Insights > IND

News List

I-Mab gets IND approval for TJC4 antibody biospectrumasia
July 15, 2019
TJC4 is a potential global best-in-class CD47 Monoclonal Antibody developed for the treatment of advanced malignant tumors
Bioinvent Receives IND Approval for Phase I/iia Trial of Anti-fcyriib Antibody americanpharmaceuticalreview
July 04, 2019
BioInvent has received authorization from the U.S. Food and Drug Administration (FDA) to proceed with an Investigational New Drug (IND) application for a Phase I/IIa clinical trial of an immune-modulatory anti-FcγRllB antibody in combination with an anti-
ContraVir Pharmaceuticals Submits IND for NASH Drug contractpharma
June 28, 2019
IND positions NASH as a second indication for CRV431, in addition to HBV.
Epygenix Submits IND Application for EPX-100 for Dravet Syndrome americanpharmaceuticalreview
June 26, 2019
Epygenix Therapeutics announced the Company has submitted Investigational New Drug Application (IND) and Fast Track Designation Request for EPX-100 to the U.S. Food and Drug Administration (FDA) for the treatment of patients with Dravet syndrome.
Aclaris Therapeutics Submits IND for RA Treatment contractpharma
June 14, 2019
If the IND is allowed by the FDA, Aclaris plans to initiate a Phase 1 trial of ATI-450, an oral MK2 inhibitor in 2H19
FDA Approves IND Application to Initiate Relapsed or Refractory AML Clinical Trial americanpharmaceuticalreview
May 30, 2019
BioTheryX announced the U.S. Food and Drug Administration (FDA) has cleared BioTheryX's investigational new drug application (IND) for BTX-A51, an oral multi-kinase inhibitor, for the treatment of patients with ...
Wellspring Biosciences Announces IND Clearance to Start Trial of ARS-3248 americanpharmaceuticalreview
May 22, 2019
Wellspring Biosciences announced the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for ARS-3248, a small molecule KRAS G12C inhibitor.
Wellspring Biosciences, Janssen Receive IND Clearance contractpharma
May 20, 2019
anssen Biotech will conduct the Phase I trial for ARS-3248, a small molecule KRAS G12C inhibitor.
Wellspring Biosciences Announces IND Application Clearance to Initiate ARS-3248 Trial americanpharmaceuticalreview
May 17, 2019
Wellspring Biosciences, a wholly owned subsidiary of Araxes Pharma, announced the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for ARS-3248 ...
Albireo Announces FDA Clearance of IND to Commence Phase 2 Trial of Elobixibat for the Treatment of NAFLD/NASH drugs
April 18, 2019
Albireo Announces FDA Clearance of IND to Commence Phase 2 Trial of Elobixibat for the Treatment of NAFLD/NASH

Previous page 1 2 3 4 5 Next page